RESUMO
This is a case report of a 67-year-old patient with castration resistant metastatic prostate cancer who developed an immune-mediated large vessel vasculitis following treatment with ipilimumab (anti-CTLA-4) and nivolumab (anti-PD-1).
Assuntos
Inibidores de Checkpoint Imunológico/efeitos adversos , Vasculite/induzido quimicamente , Vasculite/diagnóstico , Idoso , Antineoplásicos Imunológicos/efeitos adversos , Humanos , Ipilimumab/efeitos adversos , Masculino , Nivolumabe/efeitos adversos , Vasculite/tratamento farmacológicoRESUMO
Eribulin is a novel microtubule-targeting agent that is approved for the treatment of patients with locally advanced or metastatic breast cancer who have previously received treatment with an anthracycline and a taxane in either the adjuvant or metastatic setting. Eribulin induces mitotic catastrophe leading to cell death but has other important antitumor effects, including reversal of epithelial-mesenchymal transition and remodeling of the tumor vasculature. Eribulin was licensed for the treatment of advanced breast cancer based on results from two large randomized Phase III clinical trials. Current clinical trials of eribulin for breast cancer are evaluating response to treatment earlier in the patient pathway and in combination with other therapeutic agents. This review provides a short overview of emerging new data on the mode of action of eribulin in breast cancer.
